

Rabbit Anti-EGFR (L858R Mutant Specific) [MD27R]: RM0330, RM0330RTU7

Intended Use: For Research Use Only

Description: Two types of mutations account for approximately 90% of mutated cases: a specific point mutation, L858R, which occurs in exon 21 and short in-frame deletions in exon 19. A common lesion in exon 19 is the deletion of E746-A750, although other variants occur. IHC-based EGFR E746-A750del specific antibody is designed to detect deletion of E746-A750 in exon 19. Deletion in exon 19 is associated with response of non-small cell lung carcinoma (NSCLC) to gefitinib or erlotinib monotherapy.


Specifications:

Clone: MD27R
 Source: Rabbit
 Isotype: IgG
 Reactivity: Human
 Immunogen: Synthetic peptide of EGFR residues aa800-900 (mutated L858R)
 Localization: Cytoplasm, membrane
 Formulation: Antibody in PBS pH7.4, containing BSA and $\leq 0.09\%$ sodium azide (NaN₃)
 Storage: Store at 2°- 8°C.
 Applications: IHC
 Package:

Description	Catalog No.	Size
EGFR (L858R Mutant Specific) Concentrated	RM0330	1 ml
EGFR (L858R Mutant Specific) Prediluted	RM0330RTU7	7 ml

IHC Procedure*:

Positive Control Tissue: Lung carcinoma L858R mutant specific
 Concentrated Dilution: 50-200
 Pretreatment: Tris EDTA pH9.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
 Incubation Time and Temp: 30-60 minutes @ RT
 Detection: Refer to the detection system manual
 * Result should be confirmed by an established diagnostic procedure.



FFPE human placenta stained with anti-EGFR (L858R mutant specific) using DAB

References:

1. Special AT-rich sequence-binding protein-1 participates in the maintenance of breast cancer stem cells through regulation of the Notch signaling pathway and expression of Snail1 and Twist1. Sun, Z. et al. Molecular medicine reports. 11: 3235-542, 2015.
2. The jagged-2/notch-1/hes-1 pathway is involved in intestinal epithelium regeneration after intestinal ischemia-reperfusion injury. Chen, G. et al. PloS one, 2013.
3. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. Sangodkar, J., Dhawan, N. S., et al. In The Journal of Clinical Investigation on 1 July, 2012.
4. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Kawahara, A., Yamamoto, C., et al. In Clinical Cancer Research on 15 June 2010.